Discussion In these analyses, we have demonstrated that the differences in costs associated with either of three preferred empirical antibiotic treatment strategies (i.e., beta-lactam monotherapy, beta-lactam/macrolide combination therapy, or fluoroquinolone monotherapy) for patients hospitalized for community-acquired pneumonia did not reach statistical significance.
← all excerpts
Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
1
—
—